These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 729611)

  • 1. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
    Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.
    Kerr MJ; Harron DW; Kinney C; Shanks RG
    Br J Clin Pharmacol; 1981 Dec; 12(6):869-71. PubMed ID: 6122463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
    Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of pindolol.
    Aellig WH
    Am Heart J; 1982 Aug; 104(2 Pt 2):346-56. PubMed ID: 6125094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet.
    Aellig WH; Narjes HH; Nüesch E; Oertle RJ; Devos JE; Pacha W
    Eur J Clin Pharmacol; 1981; 20(3):179-83. PubMed ID: 7286035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.
    West MJ; Kendall MJ; Mitchard M; Faragher EB
    Br J Clin Pharmacol; 1976 Jun; 3(3):439-43. PubMed ID: 788749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
    Leahey WJ; Neill JD; Varma MP; Shanks RG
    Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers.
    Moppert J; Degen PH; Racine-Poon A
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):197S-201S. PubMed ID: 2988591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.
    Racine-Poon A; Moppert J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):143S-149S. PubMed ID: 4005116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.
    Bobik A; Jennings GL; Korner PI; Ashley P; Jackman G
    Br J Clin Pharmacol; 1979 Jun; 7(6):545-9. PubMed ID: 465276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.
    Aellig WH; Nüesch E; Engel G; Grevel J; Niederberger W; Rosenthaler J
    Br J Clin Pharmacol; 1986 Jan; 21(1):45-51. PubMed ID: 2868747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
    Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
    J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with sustained-release oxprenolol (slow trasicor) in the management of hypertension in general practice.
    Forrest WA
    J Int Med Res; 1979; 7(4):318-23. PubMed ID: 488521
    [No Abstract]   [Full Text] [Related]  

  • 15. The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat.
    Abrahamsson T
    Br J Pharmacol; 1986 Apr; 87(4):657-64. PubMed ID: 2871880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopharmacological studies with pindolol following intravenous and oral administration].
    Aellig WH
    Adv Clin Pharmacol; 1976; 11():9-13. PubMed ID: 1032575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.
    Bowles MJ; Khurmi NS; O'Hara MJ; Raftery EB
    Eur J Clin Pharmacol; 1987; 32(2):127-33. PubMed ID: 3556193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiments with pindolol (Visken) in healthy volunteers.
    Aellig WH
    Med J Aust; 1977 Sep; 2(SP2):8-11. PubMed ID: 927284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of propranolol, pindolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetized dogs.
    Kantelip JP; Duchene-Marullaz P; Delaigue-Fabry R; Eschalier A
    Br J Clin Pharmacol; 1982; 13(Suppl 2):159S-166S. PubMed ID: 6125165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.
    Aellig WH
    Br J Clin Pharmacol; 1976 Apr; 3(2):251-7. PubMed ID: 973959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.